The HERPUD2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the HERPUD2 gene in HeLa cells. This loss-of-function model facilitates the study of the ER stress-inducible protein HERPUD2, which operates in the unfolded protein response (UPR) and ER-associated degradation (ERAD) pathways. The polyclonal format captures a spectrum of gene disruptions, avoiding clonal selection artifacts and enabling robust analysis of HERPUD2-dependent phenotypes in drug screening and functional genomics applications.
The host cell model is the HeLa cell line, a human cervical adenocarcinoma epithelial line harboring HPV-18, known for its adherent morphology and widespread use in cancer and cell biology research. HeLa cells offer a robust, well-characterized platform for gene-editing applications, with established protocols for stress pathway analysis. Their retention of UPR and ERAD signaling components makes them an ideal background for studying HERPUD2-mediated ER homeostasis in the context of malignant transformation.
HERPUD2 is an ER-resident protein induced by ER stress via the UPR sensors ATF6, IRE1??, and PERK, leading to downstream activation of XBP1 and ATF4. It functions within the ERAD machinery by associating with the HRD1-SEL1L ubiquitin ligase complex, adaptors such as VIMP and Derlin-1, and the AAA-ATPase p97/VCP. This network facilitates the retrotranslocation and proteasomal degradation of misfolded ER proteins, thereby attenuating UPR signaling and dampening apoptotic pathways. Through these interactions, HERPUD2 serves as a critical modulator of ER proteostasis and cell survival under stress conditions.
Disruption of HERPUD2 in HeLa cells creates a tailored model to explore ER stress responses in cervical carcinoma. HeLa cells may depend on HERPUD2 to cope with constitutive proteotoxic stress driven by viral oncoproteins and high metabolic demand. Loss of HERPUD2 is expected to alter UPR signal dynamics, impede ERAD substrate clearance, and sensitize cells to ER stress-inducing agents. This polyclonal knockout thus enables the dissection of adaptive stress mechanisms and the evaluation of potential therapeutic vulnerabilities in a cancer-relevant model.
Researchers can utilize this knockout model in diverse assays: western blotting of UPR markers (BiP, CHOP), RT-qPCR of ER stress genes, immunofluorescence of ER morphology, and co-immunoprecipitation of interaction partners (HRD1, p97/VCP). Pharmacological challenges with tunicamycin or thapsigargin allow functional profiling of ER stress sensitivity via apoptosis assays (Annexin V) and proteasomal activity measurements. The polyclonal population is well-suited for drug screens targeting ER stress modulators and for mechanistic studies of protein misfolding disorders. For additional information or technical support, please contact Ascent Research.
